Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1615
This examiner grants 54% of resolved cases
Danah J Al-Awadi is an examiner in Tech Center 1600, Art Unit 1615. The examiner has 814 resolved cases. The allowance rate for these cases is 54.1 percent. The median days to allowance is 1177, which is the time required for those cases to be granted. These figures offer a basis for evaluating prosecution strategies in this art unit.
The interview lift for this examiner is 13.6 percent. This figure shows the added probability of allowance associated with conducting an interview. The 13.6 percent lift is lower than the 54.1 percent allowance rate. With 814 resolved cases, the data provides a volume of outcomes for practitioners to analyze. The 1177 days to allowance serves as a benchmark for the duration of the prosecution process in Art Unit 1615. These figures assist in planning strategies for applications in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18867286 | SURFACE-MODIFIED NANODIAMOND | Non-Final OA | DAICEL CORPORATION |
| 18276834 | Endometriosis-Related Methods and Compositions | Final Rejection | The Regents of the University of California |
| 17270228 | ANTIMICROBIAL COMPOSITIONS COMPRISING CHLORHEXIDINE | Final Rejection | Solventum Intellectual Properties Company |
| 18906261 | Compositions Containing a UV-Absorbing System Including Physical UV-Attenuating Material, Trihydroxystearin and Fatty Acid Oil For Inhibiting Trihydroxystearin Crystallization | Non-Final OA | L'OREAL |
| 18543618 | ECOFRIENDLY COMPOSITIONS CONTAINING BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE | Final Rejection | L'OREAL |
| 17363624 | LIPSTICKS HAVING NATURAL OIL, FATTY ALCOHOL WAX AND FILLER PARTICLES | Final Rejection | L'OREAL |
| 18662049 | INJECTABLE PREPARATION | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 17287338 | SUNSCREEN FORMULATION | Non-Final OA | BEIERSDORF AG |
| 18974779 | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | Non-Final OA | Insmed Incorporated |
| 18032201 | HYDROPHOBIC DRUGS IN ORGANIC CORE HIGH DENSITY LIPOPROTEIN (HDL) NANOPARTICLES | Final Rejection | CITY OF HOPE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy